Vol. 29, No. 2, 2017 247 Received August 24, 2015, Revised April 7, 2016, Accepted for publication April 10, 2016 Corresponding author: Kui Young Park, Department of Dermatology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea. Tel: 82-2-6299-1525, Fax: 82-2-823-1049, E-mail: momo920@hanmail.net This is an Open Access arti...

Case report A 40-year old woman applied to the Immunology and Allergy clinic with pruritic erythematous lesions over the lateral sides of both arms and right hip within 30 minutes after the ingestion of ornizadole 500 mg tablet. She reported that five recurrent reactions emerged with the same drug on the same locations previously, and their severity was increased consecutively. She was prescrib...

PURPOSE OF REVIEW Fixed drug eruption is a simplified disease model for elucidating the mechanism(s) of how skin inflammation is induced by skin-resident T cells. In this review, we focus on how the presence of intraepidermal CD8+T cells resident in the fixed drug eruption lesions can provide exciting new clues to our understanding of pathomechanisms of inflammatory skin diseases. RECENT FIND...

Fixed drug eruptions due to ibuprofen have rarely been reported. Two days after treatment with ibuprofen, a 61-year-old woman developed erythema and pain affecting the tongue and oral mucosa. Two months later, the patient started ibuprofen and erythromycin for a catarrhal episode with reappearance of the same lesions in the oral mucosa 24 hours later. Furthermore, two new erythematosus-violaceo...

Fixed drug eruption (FDE) is characterized by recurrent well-defined lesions in the same location each time the responsible drug is taken. We report here a case of multiple FDE induced by atenolol in a 48-year-old woman confirmed by positive patch test in previously affected sites. Beta-blockers-induced FDE are very rare. Only two cases had been reported in the literature. To the best of our kn...

A case of fixed drug eruption (FDE) secondary to foscarnet is reported. This drug has recently become available on a compassionate use basis for treatment of cytomegalovirus (CMV) infection which may cause significant disease in immunosuppressed patients. Foscarnet provides a useful alternative to the only licensed anti-CMV drug currently available, namely ganciclovir (DHPG), as it has a differ...

Fixed drug eruption (FDE) is a localized type IV sensitivity reaction to a systemically introduced allergen. It usually occurs as a result of new medication, making identification and avoidance of the trigger medication straightforward; however, in a rare subset of cases no pharmacological source is identified. In such cases, the causative agent is often a food or food additive. In this report ...

Piroxicam is a nonsteroidal antiinflammatory drug (NSAID) of the oxicam group and has anti-inflammatory, analgesic, antipyretic, and antiplatelet properties. It is a potent prostaglandin inhibitor with a long half-life in plasma (36-58 hours), meaning that it can be administered in a single daily dose. Multiple adverse systemic effects have been reported for piroxicam, of which the most common ...

A 24-year-old soldier suffering from borderline tuberculoid leprosy (BT) was admitted to the Leprosy Center, Base Hospital, Lucknow for supervised institutional therapy. He was put on cap RPM 600 mg once a month and dapsone 100 mg daily . The patient developed a solitary itchy erythematous urticarial lesion of 3 .5 cm diameter with typical peau d' orange appear­ ance (Figure 1 ) , on the right ...

A 52-year-old African American female presented with severe left thigh pain of unknown etiology. She had a past medical history of generalized seizure disorder treated with phenytoin for 7 years without incident. During admission a nurse witnessed a seizure, and consequently loading and maintenance doses of phenytoin were administered to obtain a therapeutic serum concentration. The patient had...